Adjuvant FEC Versus EP in Breast Cancer (MIG5)

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 1996
In this multicenter, randomized phase III trial, node positive early breast cancer patients are randomly assigned to receive either 6 cycles of FEC (5-fluorouracil 600 mg/m2, epirubicin 60 mg/m2 and cyclophosphamide 600 mg/m2, on day 1, every three weeks) or 4 cycles of EP (epirubicin 90 mg/m2 and paclitaxel 175 mg/m2, on day 1, every three weeks). The primary study endpoint is overall survival (OS). Secondary endpoints include toxicity and event free survival (EFS).
Epistemonikos ID: 99582bfe84339b6e9365ba4566e895740fded417
First added on: May 12, 2024